Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT032
- Development stage
- Phase 2
- Lead developer
- CARsgen Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
CT032 is a humanized, autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of hematologic malignancies, primarily relapsed and/or refractory non-Hodgkin's B cell lymphoma. It uses gene-modified patient-derived T cells redirected against the CD19 antigen, resulting in immunologic cytotoxicity directed at CD19-positive cancerous B cells. The therapy is being advanced by CARsgen and Renji Hospital. The latest reported clinical development includes completion of a Phase I/II trial in China for non-Hodgkin's lymphoma, targeting patients who were relapsed or refractory after prior therapy[1][3][5].
- Other names
- Anti-CD19 chimeric antigen receptor T cell therapyAnti-CD-19 chimeric antigen receptor T cell therapyAnti-CD 19 chimeric antigen receptor T cell therapyCAR-CD19 T cellsCAR-CD-19 T cellsCAR-CD 19 T cellsCD19 Redirected Autologous CellsCD-19 Redirected Autologous CellsCD 19 Redirected Autologous Cells
02
Targets
Beyond the preview
Go deeper on CT032.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT032.